Abstract | OBJECTIVES: METHODS: A total of 50 women were enrolled in this study. The subjects were randomized equally into 2 groups: the romosozumab group or the denosumab group. Disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) and BMD at lumbar spine were evaluated. RESULTS: The percent changes (Δ) in the BMD values at 3 and 6 months for the lumbar spine were as follows: romosozumab; 4.9% and 5.2%, denosumab: 2.3% and 3.2%. The ΔBMD for the lumbar spine at 3 months was significantly higher in the romosozumab group than in the denosumab group (P = 0.044). The DAS28-ESR at baseline, 3 and 6 months in the romosozumab group were 2.88, 2.60 (P = 0.427) and 2.58 (P = 0.588), respectively. The change from baseline in DAS28-ESR did not differ significantly between these 2 groups at any time point. CONCLUSIONS: The present study revealed that romosozumab treatment is more effective than denosumab treatment in increasing BMD of the lumbar spine at 3 months. Furthermore, the present study suggested that romosozumab treatment has no effects on the disease activity of RA in patients with RA and severe osteoporosis for 6 months.
|
Authors | Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki |
Journal | Osteoporosis and sarcopenia
(Osteoporos Sarcopenia)
Vol. 7
Issue 3
Pg. 110-114
(Sep 2021)
ISSN: 2405-5263 [Electronic] Netherlands |
PMID | 34632114
(Publication Type: Journal Article)
|
Copyright | © 2021 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. |